Hepatic arterial infusion chemotherapy with gemcitabine and 5‑fluorouracil or oral S‑1 improves the prognosis of patients with postoperative liver metastases from pancreatic cancer

Tajima,Hidehiro; Kitagawa,Hirohisa; Tsukada,Tomoya; Okamoto,Koichi; Nakanuma,Shin‑Ichi; Sakai,Seisho; Makino,Isamu; Furukawa,Hiroyuki; Hayashi,Hironori; Oyama,Katsunobu; Inokuchi,Masafumi; Nakagawara,Hisatoshi; Miyashita,Tomoharu; Itoh,Hiroshi; Fujita,Hideto; Takamura,Hiroyuki; Ninomiya,Itasu; Fushida,Sachio; Fujimura,Takashi; Ohta,Tetsuo; Koda,Wataru; Minami,Tetsuya; Ryu,Yasuji; Sanada,Junichiro; Gabata,Toshifumi; Matsui,Osamu; Sai,Yoshimichi

doi:10.3892/mco.2013.152

Hepatic arterial infusion chemotherapy with gemcitabine and 5‑fluorouracil or oral S‑1 improves the prognosis of patients with postoperative liver metastases from pancreatic cancer

Authors:
- Hidehiro Tajima
- Hirohisa Kitagawa
- Tomoya Tsukada
- Koichi Okamoto
- Shin‑Ichi Nakanuma
- Seisho Sakai
- Isamu Makino
- Hiroyuki Furukawa
- Hironori Hayashi
- Katsunobu Oyama
- Masafumi Inokuchi
- Hisatoshi Nakagawara
- Tomoharu Miyashita
- Hiroshi Itoh
- Hideto Fujita
- Hiroyuki Takamura
- Itasu Ninomiya
- Sachio Fushida
- Takashi Fujimura
- Tetsuo Ohta
- Wataru Koda
- Tetsuya Minami
- Yasuji Ryu
- Junichiro Sanada
- Toshifumi Gabata
- Osamu Matsui
- Yoshimichi Sai
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa 920‑8641, Japan, Department of Radiology, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa 920‑8641, Japan, Division of Pharmacy, Kanazawa University Hospital, Kanazawa, Ishikawa 920‑8641, Japan
Published online on: July 23, 2013 https://doi.org/10.3892/mco.2013.152
Pages: 869-874

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatic metastasis is a common cause of treatment failure following resection of pancreatic cancer. In this study, we report our results of hepatic arterial infusion (HAI) chemotherapy with gemcitabine (GEM) plus 5-fluorouracil (5-FU) or oral S‑1 treatment for postoperative liver metastases from pancreatic cancer. Seven patients with postoperative liver metastases from pancreatic cancer received HAI with GEM plus 5‑FU or oral S‑1 between October, 2008 and September, 2010 at Kanazawa University Hospital (Kanazawa, Japan). Three out of the 7 cases exhibited a partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) and stable disease (SD) was achieved in 3 out of the 7 cases (response rate, 85.7%). A decrease in serum tumor marker CA 19‑9 levels was observed after 10 HAI treatment cycles in 5 out of the 7 cases. The median time to treatment failure was 8 months (range, 0‑17 months). Adverse events inluded grade 3 leukocytopenia in 1 case and anemia in all 7 cases, although 5 out of the 7 patients were anemic prior to HAI therapy. Grade 2 thrombocytopenia was also observed in 2 cases. Non‑hematological events, such as nausea, diarrhea, liver injury or neuropathy and life‑threatening toxicities were not reported; however, 6 patients (85.7%) developed catheter‑related complications and the HAI catheter and subcutaneous implantable port system had to be removed. These findings demonstrated that HAI may deliver high doses of chemotherapeutic agents directly into the tumor vessels, producing increased regional levels with greater efficacy and a lower incidence/severity of systemic side effects. In conclusion, HAI chemotherapy is a safe and effective treatment for liver metastases from pancreatic cancer.

View Figures

View References

1	International Agency for Research on Cancer, World Health Organization. Globocan 2008. World Health Organization. Website. http://globocan.iarc.fr/. Accessed October 1, 2010
2	Ishii H, Furuse J, Boku N, et al: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol. 40:573–579. 2010. View Article : Google Scholar : PubMed/NCBI
3	Evans DB, Abbruzzese JL and Willett CG: Cancer of the pancreas. Cancer: Principles and Practice of Oncology. De Vita VT, Hellman S and Rosenberg SA: 6th edition. Lippincott Williams and Wilkins; Philadelphia: pp. 1126–1161. 2001
4	Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs. observation in patients undergo curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
5	Aloia TA, Lee JE, Vauthey JN, et al: Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant chemotherapy? J Am Coll Surg. 204:347–355. 2007. View Article : Google Scholar : PubMed/NCBI
6	Sandy H, Bruckner H, Cooperman A, Paradiso J and Kiefer L: Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 89:314–327. 2000. View Article : Google Scholar
7	Ensminger WD, Rosowsky A and Raso V: A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluoroufacil. Cancer Res. 38:3784–3792. 1978.PubMed/NCBI
8	Vogl TJ, Schwarz W, Eichler K, et al: Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinoma and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol. 132:745–755. 2006. View Article : Google Scholar
9	Tse AN, Wu N, Patel D, Haviland D and Kemeny N: A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother Pharmacol. 64:935–944. 2009. View Article : Google Scholar : PubMed/NCBI
10	Van Riel JM, Peters GJ, Mammatas LH, et al: A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. Eur J Cancer. 45:2519–2527. 2009.PubMed/NCBI
11	Tajima H, Ohta T, Kitagawa H, et al: Pilot study of hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for patients with postoperative liver metastases from pancreatic cancer. Exp Therap Med. 2:265–269. 2011. View Article : Google Scholar
12	Nakamura K, Yamaguchi T, Ishihara T, et al: Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 92:2134–2139. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ueno H, Okusaka T, Ikeda M, et al: A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology. 69:421–427. 2005. View Article : Google Scholar : PubMed/NCBI
14	Nakamura K, Yamaguchi T, Ishihara T, et al: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 94:1575–1579. 2006.PubMed/NCBI
15	Ueno H, Ioka T, Ikeda M, et al: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 alone, or gemcitabine alone in patiens with locally advanced and metastatic pancreatic cacer in Japan and Taiwan: GEST study. J Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
16	Urata K, Kawasaki S, Matsunami T, et al: Calculation of child and adult standard liver volume for liver transplantation. Hepatology. 21:1317–1321. 1995.PubMed/NCBI
17	Tajima H, Ohta T, Kitagawa H, et al: Hepatic arterial infusion chemotherapy for post-operative liver metastases from pancreatic cancer in a patient with leukocytopenia: a case report. Exp Therap Med. 1:987–990. 2010.PubMed/NCBI
18	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
19	Nagakawa T, Nagamori M, Futakami F, et al: Result of extensive surgery for pancreatic carcinoma. Cancer. 77:640–645. 1996. View Article : Google Scholar : PubMed/NCBI
20	Noto M, Miwa K, Kitagawa H, et al: Pancreas head carcinoma: frequency of invasion to soft tissue adherent to the superior mesenteric artery. Am J Surg Pathol. 29:1056–1061. 2005.PubMed/NCBI
21	Homma H, Akiyama T, Mezawa S, et al: Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy. Int J Clin Oncol. 9:197–201. 2004. View Article : Google Scholar : PubMed/NCBI
22	Miyanishi K, Ishiwatari H, Hayashi T, et al: A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization. Jpn J Clin Oncol. 38:268–274. 2008. View Article : Google Scholar
23	Kikuchi K and Kanno H: Comparison for blood levels and clinical effects between tablet and other dosage forms of 5-fluorouracil (5-FU). Gan To Kagaku Ryoho. 6:559–565. 1979.(In Japanese).
24	Maruyama S, Ando M and Watayo T: Concentration of 5-FU after hepatic artery infusion chemotherapy for liver metastases of colorectal cancer. Gan To Kagaku Ryoho. 30:1635–1638. 2003.(In Japanese).
25	Tajima H, Kitagawa H, Tsukada T, et al: A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Mol Clin Oncol. 1:768–772. 2013.PubMed/NCBI
26	Nakahira S, Nakamori S, Tsujie M, et al: Pretratment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effect in pancreatic cancer xenografts. Anticancer Res. 28:179–186. 2008.PubMed/NCBI